Sign In
Buy ANTX
$4.80
+0.120 (+2.56%)
At Close: Jul 20, 2026
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
04:01pm, Wednesday, 12'th Nov 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
07:00am, Monday, 10'th Nov 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announce
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
05:03pm, Thursday, 06'th Nov 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
07:00am, Tuesday, 12'th Aug 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry pla
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
07:00am, Wednesday, 23'rd Jul 2025
MENLO PARK, Calif. & GENEVA--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX) and the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) today announced a co
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry pla
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
07:00am, Thursday, 29'th May 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
04:01pm, Tuesday, 13'th May 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
04:00pm, Tuesday, 25'th Mar 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
04:00pm, Monday, 03'rd Mar 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
AN2 Therapeutics to Participate at Upcoming Investor Conferences
07:00am, Thursday, 20'th Feb 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
04:00pm, Wednesday, 29'th Jan 2025
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
AN2 Therapeutics to Participate at Upcoming Investor Conferences
07:00am, Thursday, 14'th Nov 2024
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron c
